ide-cel 早期复发后靶向 BCMA 的双特异性抗体疗效不佳:一项法国真实世界研究
这项法国全国真实世界研究纳入 154 例 ide-cel 后复发患者,中位进展时间 6.0 个月。抗 BCMA 双特异性抗体组疗效有限,非 BCMA 双特异性抗体组总缓解率、总生存和无进展生存均更高。ide-cel 后早期复发(≤6 个月)、髓外疾病及既往治疗线数 >3 与更差结局相关。
要点
- 抗 BCMA 双特异性抗体组总缓解率 30%,非 BCMA 双特异性抗体组 67%(P = .018)。
- 非 BCMA 双特异性抗体组中位总生存 19.48 个月,抗 BCMA 组 8.41 个月(P = .034)。
- ide-cel 后 ≤6 个月复发者中位总生存 5.95 个月,>6 个月复发者 12.58 个月(P = .040)。
核心结论
- 抗 BCMA 双特异性抗体在 ide-cel 后复发患者中疗效有限,而非 BCMA 双特异性抗体可能是有前景的治疗选择。
研究设计与样本
- 法国全国真实世界研究,纳入 154 例 ide-cel 后复发患者,中位进展时间 6.0 个月(四分位距 3.0-9.9)。
- 挽救治疗包括抗 BCMA 双特异性抗体(n = 79)、靶向 GPRC5D 或 FcRH5 的非 BCMA 双特异性抗体(n = 12)、免疫调节剂联合蛋白酶体抑制剂和抗 CD38 单克隆抗体(n = 40)及其他(n = 23)。
- 试验注册号 NCT04328298。
主要发现
- 中位总生存 12.12 个月(95%CI 6.6 至未达到),中位无进展生存 3.48 个月(95%CI 2.6-6.37)。
- 双特异性抗体治疗组总缓解率(≥部分缓解)36%,其他治疗组 13%(P = .002)。
- 非 BCMA 双特异性抗体组 vs 抗 BCMA 双特异性抗体组:总缓解率 67% vs 30%(P = .018),总生存 19.48 vs 8.41 个月(P = .034),无进展生存 9.2 vs 3.81 个月(P = .035)。
- ide-cel 后早期复发(≤6 个月)与更差总生存相关:5.95 vs 12.58 个月(P = .040);髓外疾病与更差总生存相关:13.8 vs 6.28 个月(P = .033);既往治疗线数 >3 亦与更差结局相关。
临床怎么用
- 作者认为,ide-cel 后早期复发治疗策略中多样化靶点可能带来潜在获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idecabtagene vicleucel (ide-cel), an adoptive chimeric antigen receptor T-cell therapy directed against B-cell maturation antigen (BCMA), has demonstrated high response rates and improved survival in patients with relapsed/refractory multiple myeloma. However, all patients eventually relapse, and data on salvage therapy outcomes remain limited. We conducted a national, real-world study of 154 patients relapsing after ide-cel, with a median time to progression of 6.0 months (interquartile range, 3.0-9.9). Salvage therapies included anti-BCMA bispecific antibodies (BsAbs) (n = 79), non-BCMA BsAbs targeting GPRC5D or FcRH5 (n = 12), combinations of immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody (n = 40), and others (n = 23). Median overall survival (OS) was 12.12 months (95% confidence interval, 6.6 to not reached), and median progression-free survival (PFS) was 3.48 months (95% CI, 2.6-6.37). The overall response rate (≥ partial response) was higher in patients treated with BsAbs (36%) than others (13%, P = .002). Treatment with non-BCMA BsAbs resulted in significantly higher ORR (67% vs 30%, P = .018), OS (19.48 vs 8.41 months, P = .034) and PFS (9.2 vs 3.81 months, P = .035) compared to anti-BCMA BsAbs. Early relapse after ide-cel (≤6 months) was associated with worse outcomes (OS: 5.95 vs 12.58 months, P = .040), as was extramedullary disease (OS: 13.8 vs 6.28 months, P = .033) and exposure to >3 prior lines of therapy. In summary, anti-BCMA BsAbs offered limited efficacy whereas non-BCMA BsAbs may offer a promising therapeutic approach following ide-cel early relapse. These results underscore the potential benefits of diversifying targets in relapse post-ide-cel treatment strategies. This trial was registered at www.clinicaltrials.gov as #NCT04328298.
引用
- Cayla S, Karlin L, Lambert J, et al. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2026. PMID: 40966637. doi:10.1182/bloodadvances.2025017597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。